NovoCure (NVCR) Competitors

NovoCure (NASDAQ:NVCR) and Stevanato Group (NYSE:STVN) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, community ranking, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

Is NVCR or STVN more profitable?

Stevanato Group has a net margin of 10.47% compared to NovoCure's net margin of -25.93%. Stevanato Group's return on equity of 9.86% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-25.93%	-41.48%	-12.74%
Stevanato Group	10.47%	9.86%	5.79%

Do analysts recommend NVCR or STVN?

NovoCure presently has a consensus price target of $32.83, suggesting a potential upside of 80.40%. Given NovoCure's higher probable upside, equities analysts clearly believe NovoCure is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Stevanato Group	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86

Does the media prefer NVCR or STVN?

In the previous week, NovoCure had 1 more articles in the media than Stevanato Group. MarketBeat recorded 6 mentions for NovoCure and 5 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 1.14 beat NovoCure's score of 0.66 indicating that Stevanato Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Stevanato Group	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has better earnings & valuation, NVCR or STVN?

Stevanato Group has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$621.71M	3.26	-$207.04M	-$1.51	-12.05
Stevanato Group	$1.12B	6.42	$157.62M	$0.51	46.76

Does the MarketBeat Community favor NVCR or STVN?

NovoCure received 447 more outperform votes than Stevanato Group when rated by MarketBeat users. However, 63.27% of users gave Stevanato Group an outperform vote while only 62.98% of users gave NovoCure an outperform vote.

Company	Underperform	Outperform
NovoCure	Outperform Votes 478 62.98%	Underperform Votes 281 37.02%
Stevanato Group	Outperform Votes 31 63.27%	Underperform Votes 18 36.73%

Which has more risk and volatility, NVCR or STVN?

NovoCure has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Comparatively, Stevanato Group has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.

Do insiders & institutionals believe in NVCR or STVN?

84.6% of NovoCure shares are held by institutional investors. 6.3% of NovoCure shares are held by insiders. Comparatively, 0.7% of Stevanato Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Stevanato Group beats NovoCure on 12 of the 18 factors compared between the two stocks.